1. Home
  2. CSR vs CSTL Comparison

CSR vs CSTL Comparison

Compare CSR & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo D/B/A Centerspace

CSR

D/B/A Centerspace

HOLD

Current Price

$64.43

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$39.58

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CSR
CSTL
Founded
1970
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical Specialities
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.2B
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
CSR
CSTL
Price
$64.43
$39.58
Analyst Decision
Hold
Strong Buy
Analyst Count
6
6
Target Price
$70.20
$46.67
AVG Volume (30 Days)
137.1K
381.5K
Earning Date
02-17-2026
02-26-2026
Dividend Yield
4.79%
N/A
EPS Growth
N/A
N/A
EPS
1.82
N/A
Revenue
$273,450,000.00
$343,530,000.00
Revenue This Year
$7.24
$2.55
Revenue Next Year
$2.63
N/A
P/E Ratio
$35.23
N/A
Revenue Growth
5.72
10.15
52 Week Low
$52.76
$14.59
52 Week High
$69.15
$44.28

Technical Indicators

Market Signals
Indicator
CSR
CSTL
Relative Strength Index (RSI) 45.04 48.34
Support Level $63.41 $39.74
Resistance Level $66.25 $44.28
Average True Range (ATR) 1.37 1.73
MACD -0.15 -0.28
Stochastic Oscillator 21.71 25.33

Price Performance

Historical Comparison
CSR
CSTL

About CSR D/B/A Centerspace

Centerspace is a real estate investment trust (REIT) that focuses on the ownership, management, acquisitions, redevelopment, and development of apartment communities. The company operates through a single reportable segment which includes the ownership, management, development, redevelopment, and acquisition of apartment communities and conduct their corporate operations from offices in Minot, North Dakota and Minneapolis, Minnesota.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.

Share on Social Networks: